Related references
Note: Only part of the references are listed.MiR-199a-5p-containing macrophage-derived extracellular vesicles inhibit SMARCA4 and alleviate atherosclerosis by reducing endothelial cell pyroptosis
Weijie Liang et al.
CELL BIOLOGY AND TOXICOLOGY (2023)
Managing Resistance to Immune Checkpoint Inhibitors in Lung Cancer: Treatment and Novel Strategies
Antonio Passaro et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations
Aaron C. Tan et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
First-Line Immunotherapy for Non-Small-Cell Lung Cancer
Martin Reck et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Smarca4 Inactivation Promotes Lineage- Specific Transformation and Early Metastatic Features in the Lung
Carla P. Concepcion et al.
CANCER DISCOVERY (2022)
Pan-cancer analysis of ARID family members as novel biomarkers for immune checkpoint inhibitor therapy
Yan Zhu et al.
CANCER BIOLOGY & THERAPY (2022)
Immune-Desert Tumor Microenvironment in Thoracic SMARCA4-Deficient Undifferentiated Tumors with Limited Efficacy of Immune Checkpoint Inhibitors
Justine Gantzer et al.
ONCOLOGIST (2022)
Deciphering the tumor microenvironment cell-infiltrating landscape reveals microenvironment subtypes and therapeutic potentials for nonsquamous NSCLC
Hao Chen et al.
JCI INSIGHT (2022)
Clinically-meaningful improvements in therapy for unresectable NSCLC
Seigo Katakura et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2022)
cBAF complex components and MYC cooperate early in CD8+ T cell fate
Ao Guo et al.
NATURE (2022)
SMARCA4-deficient lung carcinoma is an aggressive tumor highly infiltrated by FOXP3+cells and neutrophils
Yoan Velut et al.
LUNG CANCER (2022)
Targeting SWI/SNF ATPases in enhancer-addicted prostate cancer
Lanbo Xiao et al.
NATURE (2022)
SMARCA4 mutations in KRAS-mutant lung adenocarcinoma: a multi-cohort analysis
Liang Liu et al.
MOLECULAR ONCOLOGY (2021)
Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance
Sreya Bagchi et al.
ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 16, 2021 (2021)
STK11/LKB1 and KEAP1 mutations in non-small cell lung cancer: Prognostic rather than predictive?
Alessandro Di Federico et al.
EUROPEAN JOURNAL OF CANCER (2021)
PDL1 high expression without TP53, KEAP1 and EPHA5 mutations could better predict survival for patients with NSCLC receiving atezolizumab
Haiyong Wang et al.
LUNG CANCER (2021)
Update on genetically defined lung neoplasms: NUT carcinoma and thoracic SMARCA4-deficient undifferentiated tumors
Kyriakos Chatzopoulos et al.
VIRCHOWS ARCHIV (2021)
A Genomic-Pathologic Annotated Risk Model to Predict Recurrence in Early-Stage Lung Adenocarcinoma
Gregory D. Jones et al.
JAMA SURGERY (2021)
SMARCA4: Implications of an Altered Chromatin-Remodeling Gene for Cancer Development and Therapy
Kristina Mardinian et al.
MOLECULAR CANCER THERAPEUTICS (2021)
Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189
D. Rodriguez-Abreu et al.
ANNALS OF ONCOLOGY (2021)
A Pan-Cancer Analysis of SMARCA4 Alterations in Human Cancers
Ling Peng et al.
FRONTIERS IN IMMUNOLOGY (2021)
SMARCA2 Deficiency While Preserving SMARCA4 and SMARCB1 in Lung Neuroendocrine Carcinomas
Jasna Metovic et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Targeting ARID1A mutations in cancer
Jaren Mullen et al.
CANCER TREATMENT REVIEWS (2021)
Atezolizumab with bevacizumab, paclitaxel and carboplatin was effective for patients with SMARCA4-deficient thoracic sarcoma
Hayato Kawachi et al.
IMMUNOTHERAPY (2021)
Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With NSCLC and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021,-189, and-407
Steven F. Powell et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition
Joao V. Alessi et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Recent updates in thoracic SMARCA4-deficient undifferentiated tumor
Aruna Nambirajan et al.
SEMINARS IN DIAGNOSTIC PATHOLOGY (2021)
ARID1A, ARID1B, and ARID2 Mutations Serve as Potential Biomarkers for Immune Checkpoint Blockade in Patients With Non-Small Cell Lung Cancer
Guangsheng Zhu et al.
FRONTIERS IN IMMUNOLOGY (2021)
PD-L1 Overexpression, SWI/SNF Complex Deregulation, and Profound Transcriptomic Changes Characterize Cancer-Dependent Exhaustion of Persistently Activated CD4+ T Cells
Iga Jancewicz et al.
CANCERS (2021)
SMARCA4-Deficient Thoracic Sarcoma: A Case Report and Review of Literature
Brian D. Stewart et al.
INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY (2020)
Clinicopathologic Characteristics of BRG1-De fi cient NSCLC
Ibiayi Dagogo-Jack et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
Marina C Garassino et al.
LANCET ONCOLOGY (2020)
ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy
Ryosuke Okamura et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Small-Cell Carcinoma of the Ovary, Hypercalcemic Type-Genetics, New Treatment Targets, and Current Management Guidelines
Marc Tischkowitz et al.
CLINICAL CANCER RESEARCH (2020)
Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer
Shirish Gadgeel et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Oncogenic driver genes and tumor microenvironment determine the type of liver cancer
Gang Wang et al.
CELL DEATH & DISEASE (2020)
Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid Tumors
Sarah Abou Alaiwi et al.
CANCER IMMUNOLOGY RESEARCH (2020)
The Genomic Landscape of SMARCA4 Alterations and Associations with Outcomes in Patients with Lung Cancer
Adamj. Schoenfeld et al.
CLINICAL CANCER RESEARCH (2020)
BRG1 Loss Predisposes Lung Cancers to Replicative Stress and ATR Dependency
Manav Gupta et al.
CANCER RESEARCH (2020)
Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT) beyond SMARCA4 Mutations: A Comprehensive Genomic Analysis
Aurelie Auguste et al.
CELLS (2020)
KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden
D. Marinelli et al.
ANNALS OF ONCOLOGY (2020)
A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407
Luis Paz-Ares et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Loss of SWI/SNF Chromatin Remodeling Alters NRF2 Signaling in Non-Small Cell Lung Carcinoma
Shujie Song et al.
MOLECULAR CANCER RESEARCH (2020)
The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies
Shogo Kumagai et al.
NATURE IMMUNOLOGY (2020)
Mammalian SWI/SNF Chromatin Remodeling Complexes: Emerging Mechanisms and Therapeutic Strategies
Richard C. Centore et al.
TRENDS IN GENETICS (2020)
Comprehensive genomic profile of Chinese lung cancer patients and mutation characteristics of individuals resistant to icotinib/gefitinib
Yanhong Shang et al.
SCIENTIFIC REPORTS (2020)
Functional characterization of SMARCA4 variants identified by targeted exome-sequencing of 131,668 cancer patients
Tharu M. Fernando et al.
NATURE COMMUNICATIONS (2020)
Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes
Deborah B. Doroshow et al.
CLINICAL CANCER RESEARCH (2019)
SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer
Yibo Xue et al.
NATURE COMMUNICATIONS (2019)
CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary
Yibo Xue et al.
NATURE COMMUNICATIONS (2019)
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
Howard West et al.
LANCET ONCOLOGY (2019)
Successful treatment with nivolumab for SMARCA4-deficient non-small cell lung carcinoma with a high tumor mutation burden: A case report
Tomoyuki Naito et al.
THORACIC CANCER (2019)
Five-Year Overall Survival for Patients With Advanced Non-Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study
Edward B. Garon et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design
William Farnaby et al.
NATURE CHEMICAL BIOLOGY (2019)
Mechanisms of immunotherapy resistance: lessons from glioblastoma
Christopher M. Jackson et al.
NATURE IMMUNOLOGY (2019)
Exceptionally rapid response to pembrolizumab in a SMARCA4-deficient thoracic sarcoma overexpressing PD-L1: A case report
Kohichi Takada et al.
THORACIC CANCER (2019)
Degron mediated BRM/SMARCA2 depletion uncovers novel combination partners for treatment of BRG1/SMARCA4-mutant cancers
Florencia Rago et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2019)
M2 Macrophage-Derived Exosomes Promote Cell Migration and Invasion in Colon Cancer
Jingqin Lan et al.
CANCER RESEARCH (2019)
Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11
Linnea La Fleur et al.
LUNG CANCER (2019)
Targeting of BRM Sensitizes BRG1-Mutant Lung Cancer Cell Lines to Radiotherapy
Erika Zernickel et al.
MOLECULAR CANCER THERAPEUTICS (2019)
Non-small cell lung cancer with loss of expression of the SWI/SNF complex is associated with aggressive clinicopathological features, PD-L1-positive status, and high tumor mutation burden
Tomoyuki Naito et al.
LUNG CANCER (2019)
Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy
Ferdinandos Skoulidis et al.
NATURE REVIEWS CANCER (2019)
Dominant-negative SMARCA4 mutants alter the accessibility landscape of tissue-unrestricted enhancers
H. Courtney Hodges et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2018)
Dominant-negative SMARCA4 mutants alter the accessibility landscape of tissue-unrestricted enhancers
H. Courtney Hodges et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2018)
Immune-Active Microenvironment in Small Cell Carcinoma of the Ovary, Hypercalcemic Type: Rationale for Immune Checkpoint Blockade
Petar Jelinic et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
An inhibitor of oxidative phosphorylation exploits cancer vulnerability
Jennifer R. Molina et al.
NATURE MEDICINE (2018)
Mutations in the SWI/SNF complex induce a targetable dependence on oxidative phosphorylation in lung cancer
Yonathan Lissanu Deribe et al.
NATURE MEDICINE (2018)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing
Deng Pan et al.
SCIENCE (2018)
Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma
Diana Miao et al.
SCIENCE (2018)
Immune-Active Microenvironment in Small Cell Carcinoma of the Ovary, Hypercalcemic Type: Rationale for Immune Checkpoint Blockade
Petar Jelinic et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Induction of innate immune memory via microRNA targeting of chromatin remodelling factors
John J. Seeley et al.
NATURE (2018)
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer
L. Paz-Ares et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Smarca4 ATPase mutations disrupt direct eviction of PRC1 from chromatin
Benjamin Z. Stanton et al.
NATURE GENETICS (2017)
ARID1A loss impairs enhancer-mediated gene regulation and drives colon cancer in mice
Radhika Mathur et al.
NATURE GENETICS (2017)
Clinicopathological and molecular characterization of SMARCA4-deficient thoracic sarcomas with comparison to potentially related entities
Akihiko Yoshida et al.
MODERN PATHOLOGY (2017)
Proliferation of PD-1+CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients
Alice O. Kamphorst et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
PRC2-mediated repression of SMARCA2 predicts EZH2 inhibitor activity in SWI/SNF mutant tumors
Thomas Januario et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
SMARCA4-deficient pulmonary adenocarcinoma: clinicopathological, immunohistochemical, and molecular characteristics of a novel aggressive neoplasm with a consistent TTF1neg/CK7pos/HepPar-1pos immunophenotype
Abbas Agaimy et al.
VIRCHOWS ARCHIV (2017)
SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers
Vural Tagal et al.
NATURE COMMUNICATIONS (2017)
AACR Project GENIE: Powering Precision Medicine through an International Consortium
Fabrice Andre et al.
CANCER DISCOVERY (2017)
SMARCA4/BRG1 Is a Novel Prognostic Biomarker Predictive of Cisplatin-Based Chemotherapy Outcomes in Resected Non-Small Cell Lung Cancer
Erica Hlavin Bell et al.
CLINICAL CANCER RESEARCH (2016)
Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type
Anthony N. Karnezis et al.
JOURNAL OF PATHOLOGY (2016)
PRC2 and SWI/SNF Chromatin Remodeling Complexes in Health and Disease
Cigall Kadoch et al.
BIOCHEMISTRY (2016)
SMARCA4/Brg1 coordinates genetic and epigenetic networks underlying Shh-type medulloblastoma development
X. Shi et al.
ONCOGENE (2016)
The occurrence of intracranial rhabdoid tumours in mice depends on temporal control of Smarcb1 inactivation
Zhi-Yan Han et al.
NATURE COMMUNICATIONS (2016)
The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNFMutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies
Bhavatarini Vangamudi et al.
CANCER RESEARCH (2015)
Genomic Characterization of Non-Small-Cell Lung Cancer in African Americans by Targeted Massively Parallel Sequencing
Luiz H. Araujo et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Synthetic lethality in chronic lymphocytic leukaemia with DNA damage response defects by targeting the ATR pathway
Marwan Kwok et al.
LANCET (2015)
EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors
Christine M. Fillmore et al.
NATURE (2015)
SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas
Francois Le Loarer et al.
NATURE GENETICS (2015)
Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition
Fiona K. Middleton et al.
ONCOTARGET (2015)
The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo
Frank P. Vendetti et al.
ONCOTARGET (2015)
Expression inactivation of SMARCA4 by microRNAs in lung tumors
Isabel F. Coira et al.
HUMAN MOLECULAR GENETICS (2015)
Vulnerabilities of Mutant SWI/SNF Complexes in Cancer
Katherine C. Helming et al.
CANCER CELL (2014)
BRG1/SMARCA4 Inactivation Promotes Non-Small Cell Lung Cancer Aggressiveness by Altering Chromatin Organization
Tess Orvis et al.
CANCER RESEARCH (2014)
Molecular Pathways: SWI/SNF (BAF) Complexes Are Frequently Mutated in Cancer-Mechanisms and Potential Therapeutic Insights
Xiaofeng Wang et al.
CLINICAL CANCER RESEARCH (2014)
Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
Mark G. Kris et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Residual Complexes Containing SMARCA2 (BRM) Underlie the Oncogenic Drive of SMARCA4 (BRG1) Mutation
Boris G. Wilson et al.
MOLECULAR AND CELLULAR BIOLOGY (2014)
Recurrent SMARCA4 mutations in small cell carcinoma of the ovary
Petar Jelinic et al.
NATURE GENETICS (2014)
ARID1B is a specific vulnerability in ARID1A-mutant cancers
Katherine C. Helming et al.
NATURE MEDICINE (2014)
Functional epigenetics approach identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers
Gregory R. Hoffman et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
A Synthetic Lethality-Based Strategy to Treat Cancers Harboring a Genetic Deficiency in the Chromatin Remodeling Factor BRG1
Takahiro Oike et al.
CANCER RESEARCH (2013)
Lung cancer with loss of BRG1/BRM, shows epithelial mesenchymal transition phenotype and distinct histologic and genetic features
Daisuke Matsubara et al.
CANCER SCIENCE (2013)
Reversible Disruption of mSWI/SNF (BAF) Complexes by the SS18-SSX Oncogenic Fusion in Synovial Sarcoma
Cigall Kadoch et al.
CELL (2013)
BRG1-mediated immune tolerance: facilitation of Treg activation and partial independence of chromatin remodelling
Barbara H. Chaiyachati et al.
EMBO JOURNAL (2013)
Inactivating Mutations in SWI/SNF Chromatin Remodeling Genes in Human Cancer
Takahiro Oike et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2013)
Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy
Cigall Kadoch et al.
NATURE GENETICS (2013)
The Spectrum of SWI/SNF Mutations, Ubiquitous in Human Cancers
A. Hunter Shain et al.
PLOS ONE (2013)
Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing
Marcin Imielinski et al.
CELL (2012)
An essential role for a mammalian SWI/SNF chromatin-remodeling complex during male meiosis
Yuna Kim et al.
DEVELOPMENT (2012)
The tumour suppressor and chromatin-remodelling factor BRG1 antagonizes Myc activity and promotes cell differentiation in human cancer
Octavio A. Romero et al.
EMBO MOLECULAR MEDICINE (2012)
Downregulation of SWI/SNF chromatin remodeling factor subunits modulates cisplatin cytotoxicity
Anbarasi Kothandapani et al.
EXPERIMENTAL CELL RESEARCH (2012)
First-Line Systemic Therapy Practice Patterns and Concordance With NCCN Guidelines for Patients Diagnosed With Metastatic NSCLC Treated at NCCN Institutions
Carrie Zornosa et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2012)
Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations
Trevor J. Pugh et al.
NATURE (2012)
The genetic landscape of mutations in Burkitt lymphoma
Cassandra Love et al.
NATURE GENETICS (2012)
A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations
Luis I. Toledo et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2011)
SWI/SNF nucleosome remodellers and cancer
Boris G. Wilson et al.
NATURE REVIEWS CANCER (2011)
Phosphorylation of MLL by ATR is required for execution of mammalian S-phase checkpoint
Han Liu et al.
NATURE (2010)
Heterogeneous SWI/SNF chromatin remodeling complexes promote expression of microphthalmia-associated transcription factor target genes in melanoma
B. Keenen et al.
ONCOGENE (2010)
The Biology of Chromatin Remodeling Complexes
Cedric R. Clapier et al.
ANNUAL REVIEW OF BIOCHEMISTRY (2009)
The SWI/SNF Chromatin Remodeling Complex Regulates Myocardin-Induced Smooth Muscle-Specific Gene Expression
Jiliang Zhou et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2009)
BRG1 and LKB1: tales of two tumor suppressor genes on chromosome 19p and lung cancer
Salvador Rodriguez-Nieto et al.
CARCINOGENESIS (2009)
The SWI/SNF complex and cancer
D. Reisman et al.
ONCOGENE (2009)
Manipulation of SMARCA2 and SMARCA4 transcript levels in porcine embryos differentially alters development and expression of SMARCA1, SOX2 NANOG, and EIF1
Luca Magnani et al.
REPRODUCTION (2009)
Microenvironmental regulation of metastasis
Johanna A. Joyce et al.
NATURE REVIEWS CANCER (2009)
Characterization of mammary tumors from Brg1 heterozygous mice
S. J. Bultman et al.
ONCOGENE (2008)
The reversible epigenetic silencing of BRM: implications for clinical targeted therapy
S. Glaros et al.
ONCOGENE (2007)
An essential switch in subunit composition of a chromatin remodeling complex during neural development
Julie Lessard et al.
NEURON (2007)
Aurora-A: the maker and breaker of spindle poles
Alexis R. Barr et al.
JOURNAL OF CELL SCIENCE (2007)
Che-1 phosphorylation by ATM/ATR and Chk2 kinases activates p53 transcription and the G2/M checkpoint
Tiziana Bruno et al.
CANCER CELL (2006)
BRG1 loss in MiaPaCa2 cells induces an altered cellular morphology and disruption in the organization of the actin cytoskeleton
GB Rosson et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2005)
Transcriptional targets of the chromatin-remodelling factor SMARCA4/BRG1 in lung cancer cells
PP Medina et al.
HUMAN MOLECULAR GENETICS (2005)
The expression of the SWI/SNF ATPase subunits BRG1 and BRM in normal human tissues
DN Reisman et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2005)
Chromatin remodeling factors and BRM/BRG1 expression as prognostic indicators in non-small cell lung cancer
J Fukuoka et al.
CLINICAL CANCER RESEARCH (2004)
Genetic and epigenetic screening for gene alterations of the chromatin-remodeling factor, SMARCA4/BRGI, in lung tumors
PP Medina et al.
GENES CHROMOSOMES & CANCER (2004)
The role of Brg1, a catalytic subunit of mammalian chromatin-remodeling complexes, in T cell development
TC Gebuhr et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
Tobacco carcinogens, their biomarkers and tobacco-induced cancer
SS Hecht
NATURE REVIEWS CANCER (2003)
Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes
L Zou et al.
SCIENCE (2003)
Highly penetrant, rapid tumorigenesis through conditional inversion of the tumor suppressor gene Snf5
CWM Roberts et al.
CANCER CELL (2002)
Concomitant down-regulation of BRM and BRG1 in human tumor cell lines: differential effects on RB-mediated growth arrest vs CD44 expression
DN Reisman et al.
ONCOGENE (2002)
LKB1 associates with Brg1 and is necessary for Brg1-induced growth arrest
PA Marignani et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
The BRG-1 subunit of the SWI/SNF complex regulates CD44 expression
MW Strobeck et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
A Brg1 null mutation in the mouse reveals functional differences among mammalian SWI/SNF complexes
S Bultman et al.
MOLECULAR CELL (2000)
Functional interactions between BRCA1 and the checkpoint kinase ATR during genotoxic stress
RS Tibbetts et al.
GENES & DEVELOPMENT (2000)
BRCA1 is associated with a human SWI/SNF-related complex: Linking chromatin remodeling to breast cancer
DA Bochar et al.
CELL (2000)
Share Paper
